arrow_back Back to App

Limiting Funds for National Institutes of Health in 2024

This bill proposes to limit the available funds for the Department of Health and Human Services, National Institutes of Health (NIH) Office of the Director for fiscal year 2024. This means NIH will have a maximum of $1.9 billion, which could impact the scope of medical research and health programs funded by the institution. For citizens, this might lead to a potential slowdown in progress in certain disease research areas.
Key points
The bill sets an upper spending limit for the National Institutes of Health (NIH) Office of the Director for 2024 at $1,909,075,000.
This funding limitation may affect NIH's ability to conduct medical research and support health programs, potentially delaying the development of new treatments and medicines.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_1999
Sponsor: Rep. Biggs, Andy [R-AZ-5]
Process start date: 2023-03-29
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To provide for a limitation on availability of funds for Department of Health and Human Services, National Institutes of Health Office of the Director for fiscal year 2024.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_1999.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-29.

What are the main provisions?

Key points include:

  • The bill sets an upper spending limit for the National Institutes of Health (NIH) Office of the Director for 2024 at $1,909,075,000.
  • This funding limitation may affect NIH's ability to conduct medical research and support health programs, potentially delaying the development of new treatments and medicines.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Biggs, Andy [R-AZ-5].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health Public Investments